Engflag

Panse

Quick links to important sections

Panse

Panse_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Panse

Property Description
Active Ingredient Pancreatin (Lipase, Amylase, Protease)
Form Gastro-resistant / Enteric-Coated Tablets
Pharmacological Class Digestive Enzyme Preparation
General Purpose Enzyme Replacement Therapy (ERT)
Origin Biologically Derived (Typically Porcine)

Panse is a Pancreatin-based medication classified as a digestive enzyme preparation, specifically designed for Enzyme Replacement Therapy (ERT). Its fundamental identity is that of an essential therapeutic agent used to supplement or replace the necessary enzymes required for proper nutrient assimilation.

Panse: Definition and Pharmacological Classification

The core active ingredient in Panse is Pancreatin, a complex, standardized mixture of exocrine pancreatic enzymes that the body uses naturally for digestion. Pancreatin is classified as a digestive enzyme drug, a role clinically recognized for its efficiency in addressing nutritional deficiencies related to compromised digestion.

This preparation contains three principal enzymes—lipase, which targets fats; amylase, which processes carbohydrates; and protease, which breaks down proteins. The medication’s biological origin, typically sourced from porcine pancreatic tissue, ensures these enzymes are chemically and functionally similar to those produced by the human pancreas.

Composition, Form, and Specialized Delivery

Panse is administered via the oral route and is uniquely formulated as a specialized gastro-resistant preparation, often provided as an enteric-coated tablet or capsule contents. This specific dosage form is functionally critical: the protective coating is engineered to remain intact in the high acidity of the stomach.

This acid-resistant barrier prevents the immediate inactivation of the sensitive pancreatic enzymes upon ingestion, ensuring they are instead delivered intact to the small intestine, the physiological site of digestion. This targeted release mechanism is the reason Panse can effectively deliver its essential enzymes precisely where macronutrient hydrolysis must occur for effective digestion.

General Purpose and Functional Benefit

The general purpose of Panse is to provide immediate, powerful digestion support by performing the critical work of breaking down food components. By consistently delivering the active enzymes to the digestive tract, Panse ensures that consumed nutrients are processed correctly. This crucial functional benefit helps to alleviate the difficulties and complications associated with inadequate breakdown and absorption of food, a typical neutral use scenario.

Regulatory References

  1. Pancrelipase: MedlinePlus Drug Information

What side effects are possible with Panse?

Possible Side Effects and Safety Information

The safety profile for Panse, a Pancreatin-based digestive enzyme preparation, is strictly documented by official government regulatory authorities. Adverse reactions are classified by the frequency with which they are reported.

Frequency-Classified Adverse Reactions

The majority of documented effects relate to the Gastrointestinal disorders system.

Frequency Classification System Organ Class Adverse Reaction
Common (up to 1 in 10) Gastrointestinal disorders Abdominal pain, Flatulence
Uncommon (up to 1 in 100) Gastrointestinal disorders Nausea, Vomiting, Diarrhea, Constipation
Uncommon (up to 1 in 100) Skin and Subcutaneous Tissue Disorders Rash, Urticaria

Serious Adverse Reactions and Safety Considerations

Official labeling highlights infrequent but clinically significant safety concerns. Hypersensitivity reactions, including anaphylaxis, are documented as Very Rare serious events. Additionally, Fibrosing colonopathy, a rare condition involving intestinal strictures, is noted in regulatory warnings.

This specific serious adverse reaction is associated with long-term, very high-dose exposure exceeding established therapeutic guidelines. A specific regulatory caution exists for the pediatric population with Cystic Fibrosis concerning this risk.

General safety constraints include a contraindication for individuals with known allergy to Pancreatin or porcine protein. The label also notes that Panse may potentially impact the gastrointestinal absorption of folic acid and iron as a high-level safety consequence.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation on Panse overdose focuses on specific clinical manifestations and mandated emergency actions, rather than single acute incidents.

Documented Overdose Manifestations

Overdose resulting from acute or chronic exposure may present with distinct signs. Excessive, chronic high-dose use is officially associated with the risk of fibrosing colonopathy and the development of colonic strictures, which are serious conditions documented primarily in pediatric patients with Cystic Fibrosis. Acute or high-dose exposure may lead to hyperuricemia, defined as elevated levels of uric acid in the blood. Severe gastrointestinal symptoms, including profound nausea, vomiting, or diarrhea, are also listed as possible manifestations of excessive intake.

Emergency Action Requirements

In the event of any suspected overdose, individuals must seek immediate medical attention. The official guidance dictates that you should call emergency services immediately if the exposed person collapses, has a seizure, has trouble breathing, or cannot be awakened. Treatment for Panse overdose is defined by regulatory bodies as strictly symptomatic and supportive, as no specific antidote is known to exist. Monitoring requirements include the advisability of monitoring blood uric acid levels in certain at-risk patients, reflecting the documented metabolic consequences.

Therapeutic Uses of Panse

Quick Facts

  • Primary Use: Management of specific gastrointestinal conditions.
  • Relief: Helps reduce acid production in the stomach.
  • Support: Used to facilitate the healing of ulcers.

Panse is a prescribed medication utilized for the management of conditions related to excessive stomach acid. Its primary therapeutic domains include supporting the relief of symptoms associated with gastroesophageal reflux disease (GERD), often referred to as acid reflux.

The medication is also indicated to help facilitate the healing and prevention of ulcers in both the stomach and the small intestine (duodenal ulcers). Healthcare professionals may also recommend its use as part of a regimen to address specific bacterial infections when these infections affect the digestive system.

For complex or rare conditions that involve overproduction of stomach acid, Panse may be an appropriate component of long-term care. Always consult with a qualified health professional to determine the appropriate use and duration of treatment.

Regulatory References

  1. NIH MedlinePlus therapeutic overview

Eligibility and Restrictions for Use

Panse, which contains the active ingredient pantoprazole, is a proton pump inhibitor primarily indicated for conditions related to excess stomach acid, such as erosive esophagitis associated with gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome.

Panse is generally approved for adults for short-term treatment of erosive esophagitis, as well as for the long-term management of Zollinger-Ellison syndrome and the maintenance of healing in esophagitis. It is also approved for pediatric patients aged 5 years and older for the short-term treatment of erosive esophagitis.

Contraindications and Cautions

Panse should not be used by patients who have a known hypersensitivity to pantoprazole, substituted benzimidazoles (a class of related drugs), or any other components of the formulation. It is also contraindicated for use with medications containing rilpivirine (an antiretroviral).

Caution is advised for patients with:

  • Liver disease (moderate to severe).
  • A history of systemic lupus erythematosus (SLE).
  • Risk factors for bone fractures (especially with long-term, high-dose use).
  • Risk factors for Vitamin B-12 deficiency or hypomagnesemia (low magnesium levels).

Before initiating treatment, the possibility of gastric malignancy should be ruled out, as the drug can mask its symptoms.

What should I know about interactions with other medicines?

The use of Panse, which significantly elevates gastric mathrmpH, carries a risk of pharmacokinetic drug-drug interactions, primarily through two mechanisms: alteration of drug absorption and modulation of hepatic enzymes.

Interactions based on Gastric pH Change

Panse can reduce the absorption and therapeutic effect of co-administered medicines that require an acidic stomach environment for adequate dissolution and bioavailability. This interaction is clinically significant for specific drugs such as certain antifungals (e.g., ketoconazole) and antivirals (e.g., atazanavir). Co-administration with such mathrmpH-dependent drugs is often contraindicated or requires strict procedural constraints, such as separating the administration time by several hours or using an alternative therapy.

Interactions via Metabolism

Panse has the potential to inhibit certain Cytochrome P450 (CYP) enzymes, notably CYP2C19. This enzyme inhibition can lead to increased plasma concentrations of other medicines metabolized by these pathways, which is especially important for drugs with a narrow therapeutic index (e.g., phenytoin, warfarin). Use with warfarin requires enhanced monitoring of blood clotting tests (e.g., International Normalized Ratio [INR]) and potential dose adjustment of the anticoagulant due to an increased risk of bleeding. Regulatory bodies classify these as clinically significant interactions that necessitate caution and close surveillance.

Mechanism of Action

Panse functions as a highly selective tyrosine kinase inhibitor, a mechanism focused on modulating enzyme-mediated signaling within specific biological systems. Its action is centered on directly binding to and inhibiting key targets, including the BCR-ABL fusion protein and receptor tyrosine kinases such as c-Kit and PDGFR (alpha and beta).

Panse binds to the ATP-binding pocket of these enzymes, stabilizing their inactive conformation. This interaction blocks the signal transmitted by these constitutively active proteins, thereby interrupting the phosphorylation of downstream substrates. The subsequent disruption of key internal cascades, notably the PI3K/AKT survival pathways and Ras/MapK proliferative pathways, modulates cellular fate.

This molecular cascade leads to two primary intracellular consequences: a reduction in cellular proliferation and an increase in apoptosis (programmed cell death) in cells reliant on the inhibited pathways. Furthermore, suppression of c-Kit and PDGFR signaling modulates dysregulated signaling patterns associated with cellular migration and tissue structure.

Dosage and Administration Information

How to Use Panse (Pantoprazole Sodium)

This section outlines the administration instructions for Panse, detailing the proper methods for handling and taking the medication.

Administration Overview

The correct use of Panse is dictated by the specific formulation used, covering oral and intravenous routes.

Component Oral Delayed-Release Tablet Oral Delayed-Release Suspension Granules Intravenous (IV)
Route Oral Oral; NG or G tube Intravenous Infusion or Injection
Timing May be taken with or without food. Must be taken 30 minutes prior to a meal. Not applicable (IV).
Form Handling Must be swallowed whole; do not split, chew, or crush. Do not crush or chew the granules. Administered only by a healthcare professional.
Preparation None. Mix only with applesauce or apple juice. Reconstitution and further dilution with specific solutions (e.g., 0.9% Sodium Chloride Injection, USP) is mandatory.
Age Group Adults and pediatric patients 5 years and older. Adults and pediatric patients 5 years and older. Approved for adults; pediatric use varies by region.

Procedural Instructions

The dosing schedule for Panse is typically once daily or twice daily as prescribed, with dosages commonly 40 mg. If a dose is missed, take it as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose must be skipped to avoid taking two doses concurrently.

For the oral granules, after mixing with the required liquid or food, the dose must be consumed immediately (within 10 minutes) and the container rinsed to ensure full delivery. For intravenous administration, the medicine must be administered either as a 15-minute infusion or a 2-minute injection, according to the prescribed dosage. These steps ensure the medicine is properly absorbed and adheres to the specified administration protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Panse

This section summarizes the research evidence that has explored the use of Panse (Pancreatin) as a digestive enzyme preparation for Exocrine Pancreatic Insufficiency (EPI). The overview focuses strictly on the types of studies conducted, what outcomes were measured, and what remains uncertain in the scientific literature, without offering any clinical advice or interpretation.

Evidence for Use in Exocrine Pancreatic Insufficiency (EPI) related to Cystic Fibrosis (CF)

The evidence base for Panse in individuals with EPI due to CF includes a large number of short-term Randomized Controlled Trials (RCTs) and systematic reviews. These trials were studied for both children and adults with confirmed EPI. Researchers primarily measured absorption markers, such as the Coefficient of Fat Absorption (CFA), which is a biomarker used to measure fat absorption. Studies also monitored patient-reported outcomes describing episodic or acute changes in gastrointestinal symptoms.

Studies reported measurements of the CFA in the population using the enzyme preparation were observed to be higher than in those receiving a placebo. Research highlights changes measured during the study period, with studies reporting patterns related to changes in reports of steatorrhea and descriptions of stool consistency in the observed populations.

Evidence for Use in Exocrine Pancreatic Insufficiency (EPI) related to Chronic Pancreatitis (CP)

Research exploring Panse in adults with EPI caused by Chronic Pancreatitis includes systematic reviews and meta-analyses compiling data from RCTs and observational studies. These studies explored absorption markers, as well as patient-reported outcomes describing outcomes related to systemic or functional imbalance, such as nutritional deficiencies.

The findings describe patterns observed in the studies related to absorption, with data showing that measurements of fat absorption was observed in the studied populations. Studies monitored patterns related to changes in markers of nutritional status, particularly regarding fat-soluble vitamins. Research examined patient-reported outcomes describing perceived discomfort such as abdominal pain; the findings were variable and inconsistent across the summarized clinical research.

Areas of Research Uncertainty and Study Gaps

One key limitation is the heterogeneity (variability) across the research, particularly in defining the severity of the disease and standardizing the dose of the enzyme used. Furthermore, for some common symptoms, such as abdominal pain in chronic pancreatitis, the findings were mixed, meaning the research does not consistently describe changes in this specific symptom. Finally, because the follow-up durations were limited in many high-quality trials, the research provides context but not individual predictions about long-term success or potential changes over many years of use.

Key Studies & References

  1. Pancrelipase delayed-release capsules for exocrine pancreatic insufficiency due to cystic fibrosis: a randomized, controlled trial.

Frequently Asked Questions (FAQ)

Common questions about Panse (FAQ)

Q: What is the mechanism of action of Panse?

The way Panse works is defined by its active ingredient, which appears inconsistent in available materials. If it is a proton pump inhibitor (PPI), official information states that it works by reducing acid production in the stomach. It functions by binding to and blocking the proton pump enzyme found in the cells lining the stomach. If it is a digestive enzyme preparation, the enzymes contained in the product are intended to assist in the breakdown of food. These enzymes (lipase, amylase, and protease) are responsible for hydrolyzing fats, carbohydrates, and proteins in the small intestine.

Q: Does Panse interact with other drugs, and if so, which ones?

Official regulatory documents indicate that Panse has the potential for clinically significant drug interactions, which depend on the active ingredient. If it is a PPI, there may be interactions with drugs whose absorption is dependent on stomach pH, and its use is typically contraindicated with certain antiretroviral medicines like rilpivirine. If it is a digestive enzyme, the product may be associated with decreased absorption of specific nutrients, such as folic acid and iron. A complete list of interactions can be found in the medication’s official product information.

Q: What is the main purpose of Panse?

The main intended use of Panse is determined by its active ingredient. If the medication is a PPI, official information states it is primarily indicated for addressing conditions related to excess stomach acid, such as erosive esophagitis and Zollinger-Ellison syndrome. If the medication is a digestive enzyme preparation, its main purpose is for Enzyme Replacement Therapy (ERT), which addresses Exocrine Pancreatic Insufficiency (EPI) that can result from conditions like chronic pancreatitis or cystic fibrosis.

How should Panse be stored and disposed of?

The storage and disposal of Panse (Pancreatin) must strictly follow official regulatory requirements to protect the enzyme components from degradation.

Storage Requirements

Condition Regulatory Requirement
Temperature Store at room temperature, generally not exceeding 25 C or 30 C, depending on the product label.
Container & Moisture Keep the medication in the original container and maintain it tightly closed to protect it from moisture.
Child Safety Must be kept out of the sight and reach of children.

Stability and Disposal

The product has a limited in-use stability once opened; the contents of the container must be discarded after a specific period, often 3 to 6 months, as indicated in the product's official labeling. Unused or expired Panse and any related waste material must be disposed of in accordance with local regulations, which often includes using drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Panse found in:

A-Z Index: